


WHAT IS CLAIMED IS:


1. A compound selected from:



5

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 selected from:




10

thereof.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:

1- {4- [(4- {[(3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl]carbonyl}-5-fluoropyridin-2-yl)amino]piperidin-1-yl} ethanone,
 5 (6-(2,2-difluorocyclopropyl)imidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone,
 (6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone, or
 10 (6-bromo-7-ethylimidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone.


4. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.


15

5. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.


6. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

20

7. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, which is: 1-{4-[(4-{[(3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl]carbonyl}-5-fluoropyridin-2-yl)amino]piperidin-1-yl}ethanone, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, which is: (6-(2,2-difluorocyclopropyl)imidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, which is: (6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, which is: (6-bromo-7-ethylimidazo[1,2-*a*]pyrimidin-2-yl)((3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, for treating cancer.

14. The method for treating cancer comprising administering to a patient in need thereof a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

15. The method for treating sickle cell disease comprising administering to a patient in need thereof a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

16. The method for treating hereditary persistence of foetal hemoglobin (HPFH) mutations comprising administering to a patient in need thereof a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.

5 17. The use of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.